Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Emily A. Gomme, Ph.D.

Director, High-throughput Clinical Immunoassays & Diagnostics
Pfizer

Disclosure(s): Pfizer: Stocks/Bonds

Poster(s):

2134 - A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6)
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET